Literature DB >> 3606906

Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption.

T Cundy, M N Beneton, A J Darby, W J Marshall, J A Kanis.   

Abstract

Studies of a 63-year-old woman with osteopenia due to systemic mastocytosis are reported. Delay in making the diagnosis and the occurrence of coincident medical problems meant that radiographs during a 12-year period were available for study. Skeletal symptoms began 20 years after the skin lesions of mastocytosis first appeared, but once established bone loss was rapid, particularly from cortical bone (estimated at 3.75% pa). Biochemical and histological measurements indicated a "high turnover" bone disease and treatment with inhibitors of bone resorption was assessed. Oral, but not intravenous, clodronate was effective in reducing bone turnover as judged by falls in hydroxyproline excretion (p less than 0.01) and serum alkaline phosphatase (p less than 0.01). Mithramycin and chlorambucil were ineffective. Clodronate may be beneficial in arresting bone loss in this disorder.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606906     DOI: 10.1016/8756-3282(87)90014-7

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  10 in total

1.  Histomorphometric study of mast cells in normal bone, osteoporosis and mastocytosis using a new stain.

Authors:  M J McKenna
Journal:  Calcif Tissue Int       Date:  1994-10       Impact factor: 4.333

Review 2.  Endocrine manifestations of systemic mastocytosis in bone.

Authors:  Loren Wissner Greene; Kamyar Asadipooya; Patricia Freitas Corradi; Cem Akin
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 3.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

4.  Systemic mastocytosis with skeletal involvement: a case report and review of the literature.

Authors:  Maurizio Benucci; Catia Bettazzi; Stefania Bracci; Plinio Fabiani; Laura Monsacchi; Carlo Cappelletti; Mariangela Manfredi; Stefania Ciolli
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 5.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

Review 6.  The osteoporosis of heparinotherapy and systemic mastocytosis.

Authors:  T Bardin; M Lequesne
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

7.  Regulation of normal and neoplastic human mast cell development in mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

8.  Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b.

Authors:  R Weide; K Ehlenz; W Lorenz; E Walthers; M Klausmann; K H Pflüger
Journal:  Ann Hematol       Date:  1996-01       Impact factor: 3.673

Review 9.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

Review 10.  Hematological Diseases and Osteoporosis.

Authors:  Agostino Gaudio; Anastasia Xourafa; Rosario Rapisarda; Luca Zanoli; Salvatore Santo Signorelli; Pietro Castellino
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.